| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/20/2009 | US20090208585 Stabilisation of biological materials |
| 08/20/2009 | US20090208562 Vaccine Composition Comprising a Fibronectin Binding Protein or a Fibronectin Binding Peptide |
| 08/20/2009 | US20090208550 Methods and compositions for treating hepatic diseases |
| 08/20/2009 | US20090208538 Methods and compositions for tumor vaccination and therapy |
| 08/20/2009 | US20090208537 Anti-Neovasculature Preparations for Cancer |
| 08/20/2009 | US20090208536 Composition comprising fractions or sub-fraction of leishmania promastigotes or leishmania amastigotes called fucose mannose ligand (fml) and saponin, composition for preparation of leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or leis |
| 08/20/2009 | US20090208535 Novel Methods of Diagnosis of Treatment of P. Aeruginosa Infection and Reagents Therefor |
| 08/20/2009 | US20090208534 Attenuated salmonella as a delivery system for sirna-based tumor therapy |
| 08/20/2009 | US20090208533 Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions |
| 08/20/2009 | US20090208532 Methods Of Producing Influenza Vaccine Compositions |
| 08/20/2009 | US20090208531 Antiviral agents and vaccines against influenza |
| 08/20/2009 | US20090208530 HIV polynucleotides and polypeptides derived from Botswana MJ4 |
| 08/20/2009 | US20090208529 Recombinant Novirhabdoviruses and Uses Thereof |
| 08/20/2009 | US20090208528 Empty capsids (vlps(-vp4)) of the infectious bursal disease virus (ibdv), obtainment process and applications |
| 08/20/2009 | US20090208527 Multi plasmid system for the production of influenza virus |
| 08/20/2009 | US20090208526 Combination vaccines with low dose of hib conjugate |
| 08/20/2009 | US20090208524 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 08/20/2009 | US20090208523 Adjuvant for vaccines |
| 08/20/2009 | US20090208522 Neutralizing Epitope-Based Growth Enhancing Vaccine |
| 08/20/2009 | US20090208521 Pharmaceutical compositions containing protein nma0939 |
| 08/20/2009 | US20090208520 Prrsv gp5 based compositions and methods |
| 08/20/2009 | US20090208519 Novel Neospora caninum Vaccine |
| 08/20/2009 | US20090208518 Immunogenic peptides for the treatment of prostate and breast cancer |
| 08/20/2009 | US20090208517 Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy |
| 08/20/2009 | US20090208516 Promoter for introducing a gene into a lymphocyte or blood cell and application thereof |
| 08/20/2009 | US20090208515 Vaccine composition |
| 08/20/2009 | US20090208514 Method of diagnosing esophageal cancer |
| 08/20/2009 | US20090208513 Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions |
| 08/20/2009 | US20090208512 Catalytic anti-factor VIII allo-antibodies |
| 08/20/2009 | US20090208511 Novel method for identifying diabetic patients at increased risk for pathological complications |
| 08/20/2009 | US20090208510 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 08/20/2009 | US20090208509 Pharmaceutical formulation of an antibody against IL-1R |
| 08/20/2009 | US20090208508 Novel use of ubiquitin c-terminal hydrolase-l1 |
| 08/20/2009 | US20090208507 Protein isoforms and uses thereof |
| 08/20/2009 | US20090208506 Antibodies against flagellin and uses thereof |
| 08/20/2009 | US20090208505 Mutations of the pik3ca gene in human cancers |
| 08/20/2009 | US20090208504 Polypeptides involved in immune response |
| 08/20/2009 | US20090208503 Immunotherapeutic treatment |
| 08/20/2009 | US20090208502 Apoptosis-inducing protein complexes and therapeutic use thereof |
| 08/20/2009 | US20090208501 Anti-Pathogen Immunoadhesins |
| 08/20/2009 | US20090208500 Method of producing antibodies with improved function |
| 08/20/2009 | US20090208499 adminstering N-(phosphonomethyl)-proline free of N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine to a patient to treat cosmetic conditions and medical disorders, symptoms or syndromes associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system |
| 08/20/2009 | US20090208498 Genetic Products Differentially Expressed In Tumors And The Use Thereof |
| 08/20/2009 | US20090208497 Humanized anti-cd4 antibody with immunosuppressive properties |
| 08/20/2009 | US20090208496 Humanized anti-cd4 antibody with immunosuppressive properties |
| 08/20/2009 | US20090208495 Anti-tumor effective paramyxovirus |
| 08/20/2009 | US20090208494 Humanized antibody molecules specific for il-31 |
| 08/20/2009 | US20090208493 Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors |
| 08/20/2009 | US20090208492 Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| 08/20/2009 | US20090208491 Compositions and Methods for Diagnosing and Treating Cancer |
| 08/20/2009 | US20090208490 Molecules that are able to inhibit the binding between NGF and the Trka receptor as analgesics with prolonged effect |
| 08/20/2009 | US20090208489 Antibodies That Bind OV064 and Methods of Use Therefor |
| 08/20/2009 | US20090208488 Regulation of dendritic cell functions by the DCAL-2 receptor |
| 08/20/2009 | US20090208487 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 08/20/2009 | US20090208486 Pharmaceutical composition comprising cxcr3 inhibitor |
| 08/20/2009 | US20090208485 To treat inflammatory diseases, immune diseases and cancer; N-[(1R,3S)-3-isopropyl-3-9{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)cyclopentyl]tetrahydro-2H-pyran-4-amine; side effect reduction; improved long term safety profile; oral administration; half life |
| 08/20/2009 | US20090208484 R-spondin compositions and methods of use thereof |
| 08/20/2009 | US20090208483 Antibody selective for dr4 and uses thereof |
| 08/20/2009 | US20090208482 Human obesity susceptibility gene encoding a member of the neurexin family and uses thereof |
| 08/20/2009 | US20090208451 Halogen phosphonate monoesters |
| 08/20/2009 | US20090208450 Method for enhancing the efficacy of antigen specific tumor immunotherapy |
| 08/20/2009 | US20090208422 Composition for improving efficiency of drug delivery |
| 08/20/2009 | US20090208418 Superantibody synthesis and use in detection, prevention and treatment of disease |
| 08/20/2009 | US20090208416 Monoclonal antibodies against nkg2a |
| 08/20/2009 | US20090208411 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 08/20/2009 | US20090208410 Ed-b fibronectin as stratification marker for anti-tumor drugs |
| 08/20/2009 | CA2724440A1 Strategies to prevent and/or treat immune responses to soluble allofactors |
| 08/20/2009 | CA2723314A1 Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| 08/20/2009 | CA2715611A1 Immunotherapy targeting intracellular pathogens |
| 08/20/2009 | CA2715488A1 Immunogenic control of tumours and tumour cells |
| 08/20/2009 | CA2715484A1 Elimination of immune responses to viral vectors |
| 08/20/2009 | CA2715177A1 Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus |
| 08/20/2009 | CA2715166A1 Monoclonal antibodies for tumor treatment |
| 08/20/2009 | CA2714657A1 Anti-adam-15 antibodies and utilization of the same |
| 08/20/2009 | CA2708246A1 Compositions for and methods of enhancing the immune response to antigens |
| 08/20/2009 | CA2689680A1 Fc receptor-binding polypeptides with modified effector functions |
| 08/19/2009 | EP2090657A2 Anti-IL-12 antibodies, compositions, methods and uses |
| 08/19/2009 | EP2090589A1 Albumin-fused Kunitz domain peptides |
| 08/19/2009 | EP2090586A1 Purification of her-2 variants |
| 08/19/2009 | EP2090585A1 Antigenic polypeptide usable as therapeutic agent for malignant neoplasm |
| 08/19/2009 | EP2090583A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 08/19/2009 | EP2090320A1 Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof |
| 08/19/2009 | EP2090319A2 Angiotensin peptide-carrier conjugates and uses thereof |
| 08/19/2009 | EP2090318A1 Prophylactic tuberculosis vaccine |
| 08/19/2009 | EP2089514A1 Cancerous disease modifying antibodies |
| 08/19/2009 | EP2089513A1 Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp |
| 08/19/2009 | EP2089433A2 Therapy targeting cathepsin s |
| 08/19/2009 | EP2089432A1 Anti-glycoprotein vi scfv fragment for treatment of thrombosis |
| 08/19/2009 | EP2089431A2 Methods and compositions for efficient removal of protein a from binding molecule preparations |
| 08/19/2009 | EP2089429A2 Process for preparing unaggregated antibody fc domains |
| 08/19/2009 | EP2089423A1 Antigen specific multi epitope vaccines |
| 08/19/2009 | EP2089420A2 Proteins for use in diagnosing and treating infection and disease |
| 08/19/2009 | EP2089411A2 Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
| 08/19/2009 | EP2089061A1 Inhibition of sox9 function fn the treatment of proteogl ycan-associated pathophysiological conditions |
| 08/19/2009 | EP2089059A2 Method for treating age-related macular degeneration |
| 08/19/2009 | EP2089058A2 Methods of treating hemolytic anemia |
| 08/19/2009 | EP2089057A2 Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| 08/19/2009 | EP2089056A2 Biodegradable t-cell activation device and methods |
| 08/19/2009 | EP2089055A2 Method for detecting and controlling cancer |
| 08/19/2009 | EP2089054A2 Novel compositions and uses thereof |